In May 2018, the US Food & Drug Administration approved the use of tofacitinib for the treatment of moderate to severe ulcerative colitis (UC). The drug tofacitinib represents the first Janus kinase (JAK) inhibitor approved in inflammatory bowel disease (IBD). This article will provide a practical approach to the clinical use of tofacitinib, as well as updates on other JAK inhibitors currently in development.

Upadacitinib belongs to a class of drugs called Janus kinase (JAK) inhibitors. Upadacitinib is used to treat a number of autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, eczema... Learn basic information such as indications, contraindications, dosage and side effects of the drug. Upadacitinib drug will help patients improve treatment results.